Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Feature|Articles|August 4, 2026
Inside Pharma's Patent Battleground: The Policy Changes Reshaping Generic and Biosimilar Competition
Author(s)Ed Silverman
Recent changes at the U.S. Patent and Trademark Office are making it harder to challenge pharmaceutical patents, raising concerns that slower generic and biosimilar competition could undermine efforts to lower drug costs while strengthening protections for brand-name innovators.
Advertisement
Advertisement
A key Trump administration agency is drawing controversy over policies that might slow the process for bringing lower-cost medicines to market. Over the past year, the U.S. Patent & Trademark Office (PTO) has taken several steps that were billed as preserving patents from unnecessary legal challenges and strengthening the system for protecting innovation.
Related to this article
Pharma brands with all the right information are still invisible to AI — and why silence is the bigger risk than inaccuracy.
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Inovalon's Jen Lamppa on why inaccurate self-reported data is clinical trial enrollment's costliest problem — and how RWD fixes it.
Inizio's Elaine Ferguson on why enabling purpose-driven employees to make a meaningful difference is as important as any formal talent strategy.
As GLP-1 competition shifts from molecules to prescriptions, manufacturers, pharmacies, providers, and payers are racing to own the patient journey.
Advertisement
Advertisement